Table 2.
Kaplan-Meier analysis for the association between clinical features and occurrence of HCC or severe consequences of liver diseases in LAM-resistant chronic hepatitis B patients
| Clinical and virological factors | No. of patients | HCC | Severe liver consequences | ||
|---|---|---|---|---|---|
| Cumulative incidence | P (Log Rank test)a | Cumulative incidence | P (Log Rank test)a | ||
| Sex | |||||
| Male | 101 | 5 (5.0%) | 0.339 | 7 (6.9%) | 0.775 |
| Female | 22 | 0 (0%) | 1 (4.5%) | ||
| Age (years) | |||||
| ≦ 50 | 81 | 0 (0%) | 0.001b | 1 (1.2%) | 0.001b |
| > 50 | 42 | 5 (11.9%) | 7 (16.7%) | ||
| rtM204V | |||||
| Absence | 62 | 2 (3.2%) | 0.589 | 2 (3.2%) | 0.131 |
| Presence | 61 | 3 (4.9%) | 6 (9.8%) | ||
| rtM204I | |||||
| Absence | 44 | 2 (4.5%) | 0.857 | 3 (6.8%) | 0.917 |
| Presence | 79 | 3 (3.8%) | 5 (6.3%) | ||
| rtM204V+I | |||||
| Absence | 106 | 4(3.8%) | 0.568 | 5 (4.7%) | 0.033 |
| Presence | 17 | 1 (5.9%) | 3 (17.6%) | ||
| rtL180M | |||||
| Absence | 89 | 3 (3.4%) | 0.591 | 6 (6.7%) | 0.830 |
| Presence | 34 | 2 (5.9%) | 2 (5.9%) | ||
| rtA181T | |||||
| Absence | 113 | 2 (1.8%) | < 0.001b | 4 (3.5%) | < 0.001b |
| Presence | 10 | 3 (30.0%) | 4 (40.0%) | ||
| HBeAg | |||||
| Absence | 58 | 5 (8.6%) | 0.012 | 7 (12.1%) | 0.016 |
| Presence | 65 | 0 (0%) | 1 (1.5%) | ||
| HBV-DNA (×106 copies/mL) | |||||
| ≦ 15 | 69 | 2 (2.9%) | 0.325 | 4 (5.8%) | 0.570 |
| > 15 | 54 | 3 (5.6%) | 4 (7.4%) | ||
| AST | |||||
| ≦ 2 ×UNL | 67 | 2 (3.0%) | 0.337 | 2 (3.0%) | 0.050 |
| > 2 ×UNL | 56 | 3 (5.4%) | 6 (10.7%) | ||
| ALT | |||||
| ≦ 2 ×UNL | 59 | 2 (3.4%) | 0.722 | 3 (5.1%) | 0.450 |
| > 2 ×UNL | 64 | 3 (4.7%) | 5 (7.8%) | ||
| BCP mutation | |||||
| Absence | 64 | 0 (0%) | 0.012 | 0 (0%) | 0.002b |
| Presence | 59 | 5 (8.5%) | 7 (11.9%) | ||
| Precore stop codon mutation | |||||
| Absence | 67 | 1 (1.5%) | 0.094 | 3 (4.5%) | 0.285 |
| Presence | 56 | 4 (7.1%) | 5 (8.9%) | ||
| Genotype C | |||||
| Absence | 84 | 3 (3.6%) | 0.631 | 4 (4.8%) | 0.234 |
| Presence | 39 | 2 (5.1%) | 4 (10.3%) | ||
| Pre-S internal deletions | |||||
| Absence | 91 | 4 (4.4%) | 0.749 | 6 (6.6%) | 0.941 |
| Presence | 32 | 1 (3.1%) | 2 (6.3%) | ||
| Duration of LAM treatment on entry (months) | |||||
| ≦ 12 | 80 | 2 (2.5%) | 0.798 | 4 (5.0%) | 0.361 |
| > 12 | 43 | 3 (7.0%) | 4 (9.3%) | ||
| Subsequent ADV treatment | |||||
| No | 41 | 1 (2.4%) | 0.688 | 2 (4.9%) | 0.774 |
| Yes | 82 | 4 (4.9%) | 6 (7.3%) | ||
| Subsequent ETV treatment | |||||
| No | 79 | 4 (5.1%) | 0.422 | 0 (0%) | 0.153 |
| Yes | 44 | 1 (2.3%) | 8 (18.2%) | ||
| Subsequent ETV and/or ADV treatment | |||||
| No | 21 | 1 (4.8%) | 0.284 | 1 (4.8%) | 0.181 |
| Yes | 102 | 4 (3.9%) | 7 (6.9%) | ||
| Total duration of antiviral therapy (months) | |||||
| ≦ 40 | 73 | 1 (1.4%) | 0.157 | 3 (4.1%) | 0.343 |
| > 40 | 50 | 4 (8.0%) | 5 (10%) | ||
| Cirrhosis | |||||
| No | 83 | 0 (0%) | < 0.001b | 0 (0%) | < 0.001b |
| Yes | 40 | 5 (12.5%) | 8 (20.0%) | ||
aKaplan-Meier analysis; bAccording to the method of Bonferroni correction for multiple comparisons, P < 0.0024 was considered statistically significant.